Aclaris partners with Biosion for anti-TSLP programs and seeks $80M funding, Keymed Biosciences signs $626M potential deal with Ouro Medicines, ReCode receives CF Foundation funding, Quell gets $10M ...

Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results ...

Corneal blindness is a serious public health concern in India, impacting approximately 12 lakh people and making it one of the leading causes of vision loss. This condition is primarily caused by ...

BIO is in search of dynamic, professional candidates possessing the expertise and education outlined in the job titles listed below. If you are interested in working at BIO, please visit our current ...

In accordance with its Bylaws and Articles of Incorporation, the Biotechnology Innovation Organization (BIO) is governed by its Board of Directors. The Full BIO Board of Directors is comprised of all ...

HC Wainwright reissued their buy rating on shares of KALA BIO (NASDAQ:KALA – Free Report) in a report released on Friday,Benzinga reports. The firm currently has a $15.00 price objective on the stock.

Kala Pharmaceuticals ( (KALA) ) has released its Q3 earnings. Here is a breakdown of the information Kala Pharmaceuticals presented to its ...

Normally, your cornea — the clear outer lens or "windshield" of your eye — has a dome shape, like a ball. Sometimes, the structure isn’t strong enough to hold its round shape and bulges ...

Therapeutically, EDTA has been used to remove calcified plaques that occur in the superficial cornea in band keratopathy. [19] EDTA has also been used in eye washes to aid in neutralization of ...